{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:04:56Z","timestamp":1783911896362,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["No. LTGY23H160022"],"award-info":[{"award-number":["No. LTGY23H160022"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Provincial Health Commission & Pioneer & Leading Goose R&D Program","award":["No. 2025C02120"],"award-info":[{"award-number":["No. 2025C02120"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-grade serous ovarian cancer (HGSOC) remains a lethal gynecologic malignancy with limited tools for accurately predicting PARP inhibitor (PARPi) efficacy. While promoter methylation of homologous recombination repair (HRR) genes is a potential biomarker, its clinical utility remains underexplored. This study aimed to systematically evaluate HRR gene promoter methylation profiles to predict PARPi sensitivity in HGSOC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 96 HGSOC patients receiving PARPi maintenance therapy (olaparib or niraparib). The promoter methylation status of 12 HRR genes was quantitatively assessed via pyrosequencing. Patients were stratified into PARPi-sensitive and -insensitive groups based on OReO\/ENGOT-ov38 criteria. Differential methylation sites were identified, lasso and multivariate logistic regression identified key methylation sites to construct a nomogram and a PARPi Resistance Score (PRS). PFS was analyzed by Kaplan\u2011Meier and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The PARPi-insensitive group exhibited significantly higher median methylation levels across HRR gene promoters compared to the sensitive group. Through rigorous screening, 12 CpG sites were consistently associated with PARPi response across subgroups. Through screening and LASSO regression, five CpG sites\u2014ATM_Pos1, BRCA1(2S)_Pos2, BRCA2(1S)_Pos1, BRCA2(1S)_Pos7, and RAD51D_Pos6\u2014were identified as independent predictors of PARPi sensitivity. The logistic model based on these five sites showed good discrimination, with area under the ROC curve (AUC) of 0.847 in the training set and 0.903 in the validation set; calibration and decision curve analysis supported clinical utility. Using the optimal PRS cutoff of \u2212\u00a01.023, High-PRS patients had significantly shorter median PFS (14\u00a0months vs. not reached; log\u2011rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and lower 12\u2011month PFS rate (52% vs. 97.2%). Multivariate Cox analysis confirmed PRS as the only independent prognostic factor for PFS (HR 4.85, 95% CI 2.31\u201310.20,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HRR gene promoter methylation, particularly at specific BRCA1, BRCA2 and RAD51D CpG sites, robustly predicts PARPi sensitivity and independently stratifies PFS in HGSOC patients. The nomogram and PRS provide clinically actionable tools for individualized PARPi therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-026-02159-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:33:10Z","timestamp":1779197590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HRR gene promoter methylation-guided nomogram predicts PARP inhibitor efficacy and progression-free survival in high-grade serous ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Zhihua","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"11","key":"2159_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668\u201379.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2159_CR2","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"2159_CR3","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1136\/ijgc-2024-005405","volume":"34","author":"KN Moore","year":"2024","unstructured":"Moore KN, et al. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. Int J Gynecol Cancer. 2024;34(11):1753\u201360.","journal-title":"Int J Gynecol Cancer"},{"issue":"26","key":"2159_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"2159_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"15","key":"2159_CR6","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764\u201373.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2159_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist. 2022;27(3):167\u201374.","journal-title":"Oncologist"},{"issue":"2","key":"2159_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11864-024-01176-6","volume":"25","author":"R Ratnaparkhi","year":"2024","unstructured":"Ratnaparkhi R, et al. Evaluation of homologous recombination deficiency in ovarian cancer. Curr Treat Options Oncol. 2024;25(2):237\u201360.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2159_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ygyno.2020.09.029","volume":"159","author":"EH Stover","year":"2020","unstructured":"Stover EH, et al. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020;159(3):887\u201398.","journal-title":"Gynecol Oncol"},{"key":"2159_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2022.01.037","volume":"166","author":"L Paulet","year":"2022","unstructured":"Paulet L, et al. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. Eur J Cancer. 2022;166:87\u201399.","journal-title":"Eur J Cancer"},{"key":"2159_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111771","author":"N Marconato","year":"2025","unstructured":"Marconato N, et al. Unraveling homologous recombination deficiency in ovarian cancer: A review of currently available testing platforms. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17111771.","journal-title":"Cancers (Basel)"},{"key":"2159_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ygyno.2024.01.016","volume":"184","author":"AK Wehn","year":"2024","unstructured":"Wehn AK, et al. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer. Gynecol Oncol. 2024;184:67\u201373.","journal-title":"Gynecol Oncol"},{"key":"2159_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115169","volume":"215","author":"S Quesada","year":"2025","unstructured":"Quesada S, et al. Homologous recombination deficiency in ovarian cancer: global expert consensus on testing and a comparison of companion diagnostics. Eur J Cancer. 2025;215:115169.","journal-title":"Eur J Cancer"},{"issue":"12","key":"2159_CR14","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606\u201322.","journal-title":"Ann Oncol"},{"key":"2159_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040910","author":"S Tabano","year":"2020","unstructured":"Tabano S, et al. Analysis of BRCA1 and RAD51C promoter methylation in Italian families at high-risk of breast and ovarian cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040910.","journal-title":"Cancers (Basel)"},{"key":"2159_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15050601","author":"R Bacares","year":"2025","unstructured":"Bacares R, et al. A rapid and reliable test for BRCA1 promoter hypermethylation in paraffin tissue using pyrosequencing. Diagnostics. 2025. https:\/\/doi.org\/10.3390\/diagnostics15050601.","journal-title":"Diagnostics"},{"issue":"12","key":"2159_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023;34(12):1152\u201364.","journal-title":"Ann Oncol"},{"issue":"3","key":"2159_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2159_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","volume":"53","author":"DS Kim","year":"2021","unstructured":"Kim DS, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med. 2021;53(1):42\u201351.","journal-title":"Exp Mol Med"},{"issue":"15","key":"2159_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/17501911.2025.2548756","volume":"17","author":"M Farina-Morillas","year":"2025","unstructured":"Farina-Morillas M, et al. Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches. Epigenomics. 2025;17(15):1069\u201381.","journal-title":"Epigenomics"},{"issue":"21","key":"2159_CR21","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"issue":"1","key":"2159_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19(1):107.","journal-title":"Mol Cancer"},{"key":"2159_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106162","volume":"178","author":"N Gupta","year":"2022","unstructured":"Gupta N, et al. Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer. Pharmacol Res. 2022;178:106162.","journal-title":"Pharmacol Res"},{"issue":"4","key":"2159_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/0008-5472.CAN-14-0839","volume":"75","author":"JE Jaspers","year":"2015","unstructured":"Jaspers JE, et al. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. Cancer Res. 2015;75(4):732\u201341.","journal-title":"Cancer Res"},{"issue":"11","key":"2159_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim YH, et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036\u201347.","journal-title":"Cancer Discov"},{"issue":"11","key":"2159_CR26","doi-asserted-by":"publisher","first-page":"13153","DOI":"10.18632\/oncotarget.7549","volume":"7","author":"D Wang","year":"2016","unstructured":"Wang D, et al. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. 2016;7(11):13153\u201366.","journal-title":"Oncotarget"},{"issue":"1","key":"2159_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.20517\/cdr.2022.73","volume":"6","author":"R Bayley","year":"2023","unstructured":"Bayley R, Sweatman E, Higgs MR. New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers. Cancer Drug Resist. 2023;6(1):35\u201344.","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"2159_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ijgc-2022-003698","volume":"33","author":"P Soberanis Pina","year":"2023","unstructured":"Soberanis Pina P, Lheureux S. Overcoming PARP inhibitor resistance in ovarian cancer. Int J Gynecol Cancer. 2023;33(3):364\u201376.","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"2159_CR29","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-22-3328","volume":"29","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand F, et al. Clinical relevance of BRCA1 promoter methylation testing in patients with ovarian cancer. Clin Cancer Res. 2023;29(16):3124\u20139.","journal-title":"Clin Cancer Res"},{"key":"2159_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/gpbjnl\/qzaf017","author":"Z Jia","year":"2025","unstructured":"Jia Z, et al. Evaluative methodology for HRD testing: Development of standard tools for consistency assessment. Genomics Proteomics Bioinformatics. 2025. https:\/\/doi.org\/10.1093\/gpbjnl\/qzaf017.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"2159_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249708","author":"N Sahnane","year":"2020","unstructured":"Sahnane N, et al. BRCA methylation testing identifies a subset of ovarian carcinomas without germline variants that can benefit from PARP inhibitor. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21249708.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"2159_CR32","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-21-0774","volume":"81","author":"K Nesic","year":"2021","unstructured":"Nesic K, et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res. 2021;81(18):4709\u201322.","journal-title":"Cancer Res"},{"issue":"1","key":"2159_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13148-025-01917-w","volume":"17","author":"L Nougarede","year":"2025","unstructured":"Nougarede L, et al. BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study. Clin Epigenetics. 2025;17(1):140.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"2159_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.7811","volume":"7","author":"S Torres-Esquius","year":"2024","unstructured":"Torres-Esquius S, et al. Prevalence of homologous recombination deficiency among patients with germline RAD51C\/D breast or ovarian cancer. JAMA Netw Open. 2024;7(4):e247811.","journal-title":"JAMA Netw Open"},{"issue":"16_suppl","key":"2159_CR35","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1200\/JCO.2023.41.16_suppl.5559","volume":"41","author":"H Blons","year":"2023","unstructured":"Blons H, et al. BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study. J Clin Oncol. 2023;41(16_suppl):5559\u20135559.","journal-title":"J Clin Oncol"},{"issue":"25","key":"2159_CR36","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02159-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02159-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02159-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:27:20Z","timestamp":1783909640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02159-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02159-0","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in this study. The study followed the World Medical Association Declaration of Helsinki recommendations and was approved by the Ethics Committee of Womens Hospital School of Medicine Zhejiang University (reference numbers: PRO2025-219).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests or personal relationships relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}